Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial☆☆☆
To access this article, please choose from the options below
☆ Supported by grants from Biogen, Cambridge, Mass, and The Medicines Company, Cambridge, Mass.
☆☆ Reprint requests: Elliott M. Antman, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail: eantman@rics.bwh.harvard.edu
PII: S0002-8703(02)39926-5
doi:10.1067/mhj.2002.120405
© 2002 Mosby, Inc. All rights reserved.
Refers to article:
- Publication policy, informed consent, and the randomized clinical trial
- Improved efficacy and less bleeding: Further evidence of a unique uncoupling of benefit and risk with bivalirudin
